Vyvgart (Efgartigimod) Market Size, Share & Trends Report

Vyvgart (Efgartigimod) Market (2025 - 2030) Size, Share & Trends Analysis Report By Indication (Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)), By Route of Administration, By Region, And Segment Forecasts

Market Segmentation

Vyvgart (Efgartigimod) Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Generalized Myasthenia Gravis (gMG)
- Others
Vyvgart (Efgartigimod) Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Intravenous (IV) Infusion
- Subcutaneous (SC) Injection
- Prefilled Syringe
Vyvgart (Efgartigimod) Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Vyvgart (Efgartigimod) Market, by Indication
    - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    - Generalized Myasthenia Gravis (gMG)
    - Others
  - North America Vyvgart (Efgartigimod) Market, by Route of Administration
    - Intravenous (IV) Infusion
    - Subcutaneous (SC) Injection
    - Prefilled Syringe
  - U.S.
    - U.S. Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - U.S. Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Canada
    - Canada Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Canada Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Mexico
    - Mexico Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Mexico Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
- Europe
  - Europe Vyvgart (Efgartigimod) Market, by Indication
    - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    - Generalized Myasthenia Gravis (gMG)
    - Others
  - Europe Vyvgart (Efgartigimod) Market, by Route of Administration
    - Intravenous (IV) Infusion
    - Subcutaneous (SC) Injection
    - Prefilled Syringe
  - UK
    - UK Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - UK Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Germany
    - Germany Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Germany Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - France
    - France Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - France Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Italy
    - Italy Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Italy Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Spain
    - Spain Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Spain Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Denmark
    - Denmark Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Denmark Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Sweden
    - Sweden Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Sweden Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Norway
    - Norway Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Norway Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
- Asia Pacific
  - Asia Pacific Vyvgart (Efgartigimod) Market, by Indication
    - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    - Generalized Myasthenia Gravis (gMG)
    - Others
  - Asia Pacific Vyvgart (Efgartigimod) Market, by Route of Administration
    - Intravenous (IV) Infusion
    - Subcutaneous (SC) Injection
    - Prefilled Syringe
  - China
    - China Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - China Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Japan
    - Japan Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Japan Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - India
    - India Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - India Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Australia
    - Australia Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Australia Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - South Korea
    - South Korea Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - South Korea Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Thailand
    - Thailand Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Thailand Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
- Latin America
  - Latin America Vyvgart (Efgartigimod) Market, by Indication
    - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    - Generalized Myasthenia Gravis (gMG)
    - Others
  - Latin America Vyvgart (Efgartigimod) Market, by Route of Administration
    - Intravenous (IV) Infusion
    - Subcutaneous (SC) Injection
    - Prefilled Syringe
  - Brazil
    - Brazil Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Brazil Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Argentina
    - Argentina Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Argentina Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
- Middle East & Africa
  - Middle East & Africa Vyvgart (Efgartigimod) Market, by Indication
    - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    - Generalized Myasthenia Gravis (gMG)
    - Others
  - Middle East & Africa Vyvgart (Efgartigimod) Market, by Route of Administration
    - Intravenous (IV) Infusion
    - Subcutaneous (SC) Injection
    - Prefilled Syringe
  - South Africa
    - South Africa Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - South Africa Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Saudi Arabia
    - Saudi Arabia Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Saudi Arabia Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - UAE
    - UAE Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - UAE Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe
  - Kuwait
    - Kuwait Vyvgart (Efgartigimod) Market, by Indication
      - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      - Generalized Myasthenia Gravis (gMG)
      - Others
    - Kuwait Vyvgart (Efgartigimod) Market, by Route of Administration
      - Intravenous (IV) Infusion
      - Subcutaneous (SC) Injection
      - Prefilled Syringe

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments